Top 5 Pharmacy Times Respiratory Syncytial Virus Articles of 2023
From newsworthy moments to groundbreaking research, these were the most-read respiratory syncytial virus-related articles on Pharmacy Times in 2023.
1. Patient-Reported Questionnaire Could Aid the Evaluation of Respiratory Syncytial Virus Symptoms
Findings suggest that psychometric tests used for The Respiratory Infection Intensity and Impact Questionnaire provide reliable, construct validity, and responsive evidence to detect onset symptoms of RSV. Read More Here.
Peter Hansen - stock.adobe.com
2. Immunoprophylaxis Guidance for RSV Not Aligned With Current Hospitalization Patterns, Study Finds
Investigators urge policymakers to establish flexible models that maximize coverage when respiratory syncytial virus activity is high and minimize unnecessary doses when viral activity is low. Read More Here.
3. Despite Known Health Threats of RSV, Study Finds the Public Knows Little
Less than half of respondents would recommend a vaccine against respiratory syncytial virus to a pregnant friend or family member. Read More Here.
4. Johnson & Johnson Discontinues Phase 3 Study Evaluating Respiratory Syncytial Virus Vaccine
The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021. Read More Here.
5. Experts Raise Questions, Potential Answers About Why COVID-19 Has Drastically Changed RSV Epidemiology
The prolonged lack of viral exposure has likely increased the pool of children and adults vulnerable to respiratory syncytial virus, but questions remain. Read More Here.
